Differences in the Magnitude of Wave Reflection Account for Differential Effects of Amlodipine- Versus Atenolol-Based Regimens on Central Blood Pressure: An Anglo-Scandinavian Cardiac Outcome Trial Substudy

Charlotte H. Manisty, Andrew Zambanini, Kim H. Parker, Justin E. Davies, Darrel P. Francis, Jamil Mayet, Simon A. McG Thom, Alun D. Hughes and on behalf of the Anglo-Scandinavian Cardiac Outcome Trial Investigators

_Hypertension_ 2009;54;724-730; originally published online Aug 24, 2009;
DOI: 10.1161/HYPERTENSIONAHA.108.125740

Hypertension is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 75214
Copyright © 2009 American Heart Association. All rights reserved. Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/cgi/content/full/54/4/724

Data Supplement (unedited) at:
http://hyper.ahajournals.org/cgi/content/full/HYPERTENSIONAHA.108.125740/DC1
Differences in the Magnitude of Wave Reflection Account for Differential Effects of Amlodipine-Versus Atenolol-Based Regimens on Central Blood Pressure

An Anglo-Scandinavian Cardiac Outcome Trial Substudy

Charlotte H. Manisty, Andrew Zambanini, Kim H. Parker, Justin E. Davies, Darrel P. Francis, Jamil Mayet, Simon A. McG Thom, Alun D. Hughes, on behalf of the Anglo-Scandinavian Cardiac Outcome Trial Investigators

Abstract—Antihypertensive agents may differ in their effects on central systolic blood pressure, and this may contribute to treatment-related differences in cardiovascular outcomes. In a substudy of the Anglo-Scandinavian Cardiac Outcome Trial, we investigated whether directly measured carotid systolic blood pressure differed between people randomized to amlodipine- and atenolol-based therapies and whether this is accounted for by differences in wave reflection patterns. Additional analysis was undertaken to establish whether differences in carotid systolic blood pressure predicted left ventricular mass, accounting for between-treatment differences in left ventricular mass index. Blood pressure and flow velocity were measured in the right carotid artery of 259 patients. Wave intensity analysis was used to separate and quantify forward and backward waves. Brachial blood pressure did not differ significantly between groups, but carotid systolic blood pressure (127 [12] versus 133 [15] mm Hg; \(P<0.001\)), the ratio of backward:forward pressure (0.48 [0.17] versus 0.53 [0.19]; \(P=0.01\)), and wave reflection index (19.8% [10.9%] versus 23.3% [13.3%]; \(P=0.02\)) were significantly lower in patients randomized to amlodipine-based therapy. Left ventricular mass index was also lower in this group, and adjustment for carotid blood pressure attenuated treatment differences to a greater extent than brachial blood pressure. Carotid systolic blood pressure was also a significant independent predictor of left ventricular mass index in a multivariate model. Carotid systolic blood pressure is lower in people randomized to amlodipine-based compared with atenolol-based treatment despite there being no significant difference in brachial blood pressure. This difference is attributable to a lesser magnitude of wave reflection in patients randomized to the amlodipine-based regimen. (Hypertension. 2009;54:724-730.)

Key Words: blood pressure ■ hypertension ■ wave reflection ■ wave intensity ■ pressure ■ flow

Brachial blood pressure (BP) is an important predictor of cardiovascular events; however, systolic BP (SBP) is influenced by wave reflection and varies throughout the vascular tree, with aortic (central) SBP being consistently and variably lower than brachial SBP. The importance of wave reflection in hypertension is increasingly recognized, and, more recently, indices of wave reflection have been shown to independently predict cardiovascular events.

Differential effects of antihypertensive agents on central SBP have been proposed to account for differential effects on cardiovascular and all-cause mortality, possibly as a result of changes in the timing or magnitude of wave reflection. However, not all studies have observed differential effects of antihypertensive treatments on central SBP, and the use of a generalized transfer function to estimate the central SBP from radial artery measurements has been criticized, particularly when, as in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT), the comparator therapies have different effects on heart rate. In addition, there is considerable evidence that central augmentation index, a widely used index of wave reflection, is not measured accurately using a generalized transfer function applied to the radial waveform, thereby compromising any interpretation of differences in central BP on the basis of radial measurements in terms of changes in wave reflection.
The purpose of this study, therefore, was to establish the effect of the therapeutic regimens used in ASCOT on central SBP and wave reflection using the direct measurement of carotid artery SBP (cSBP) combined with wave intensity analysis and wave separation to differentiate the direction, type, and amplitude of waves. Additional analysis was undertaken to establish whether differences in cSBP predicted left ventricular mass (LVMI) and could account for between-treatment differences in LVMI.

Methods

Subjects
A total of 259 participants (≈1 in every 3 patients) from a total of 879 participants in the Hypertension Associated Cardiovascular Disease ASCOT substudy at the St Mary’s Hospital center participated in the carotid wave intensity substudy. All of the subjects fulfilled the criteria for inclusion in the main ASCOT study. All of the patients were randomized according to the ASCOT protocol13 to a regimen of amlopidine with perindopril added as required or a regimen of atenolol with bendroflumethiazide-K added as required. Antihypertensive treatment was titrated to achieve target brachial BPs (<140/90 mm Hg for people without diabetes mellitus and <130/80 mm Hg for people with diabetes mellitus). If necessary, additional antihypertensive agents were administered according to a prespecified algorithm. Patients were also eligible for randomization to the factorial lipid-lowering arm of ASCOT if they had a total cholesterol concentration ≤5.0 mmol/L and were not taking a lipid-lowering agent at the time of randomization. Patients recruited into the lipid-lowering arm of ASCOT were randomized to receive 10 mg of atorvastatin daily or matching placebo.

Because the majority of patients received a variety of treatment before commencement of ASCOT, all of the measurements for this substudy were performed between 12 and 18 months after randomization, when study drugs had been fully uptitrated and the BP had achieved target and was stable. The study was approved by the St Mary’s Hospital Local Research Ethics Committee, and all of the subjects gave written informed consent.

Investigations

All of the studies were conducted in a temperature-controlled darkened room, with subjects having rested supine for ≥10 minutes. Brachial BP was measured after ≥5 minutes of rest using a validated, semiautomated device (Omron 705CP, Omron).18 Pressure was measured in the right common carotid artery by planar tonometry using a Millar tonometer (SPT-301, Millar Instruments Inc) and calibrated to brachial arterial pressure, as described previously.19,20 Carotid waveforms were carefully monitored during acquisition to ensure high quality and stability of recordings, over ~1 minute of measurement. Flow velocity measurements were made in the right common carotid artery by pulsed wave Doppler with an HDI 5000 ultrasound machine (Philips Medical Systems) equipped with a 7.5- to 10.0-MHz linear array transducer at a Doppler angle of 60° in a 1-mm sample volume placed in the center of the vessel ~2 cm from the carotid bulb. All of the measurements were made by a single observer, who remained masked to individual patient treatment. Details of validation of both pressure and flow measurements have been described by us previously.21 In all of the patients, the pressure data were collected first, followed by the velocity. The time taken to acquire both pressure and velocity data was ~5 minutes.

Carotid pressure and flow velocity data were sampled at a frequency of 200 Hz. After acquisition, waveforms were ensemble averaged offline, as described previously,21 using custom-written software in Matlab 5.3 (Mathworks). Care was taken to ensure that only good quality beats (generally, 6 beats) were included in the ensemble. The members of the ensemble were identified by using the peak of the R wave as the fiducial point. After constructing the ensemble, the members were checked for good temporal alignment. Occasionally, because of variability in the duration of the isovolumic contraction period, there was a small degree of misalignment (<5 ms) between the systolic rise phase of the beats, and, if this was the case, this was corrected. The cross-correlation coefficient between the initial 600 ms of each beat was also used as a quantitative measure of agreement between waveforms, with a value r>0.95 being regarded as acceptable. Local carotid artery wave velocity was calculated using the pressure–velocity loop method.21,22 Reproducibility of these methods has been published previously.21,22 and the validity of the approach has been confirmed in vitro and in vivo.23,24 The within-observer coefficient of variation was <10% for the major waves in this study and between 15% and 20% for minor waves.

In addition to measurement of carotid artery pressure and flow, all of the subjects had fasting blood samples taken and underwent echocardiography. Details of echocardiography and related measurements have been described recently elsewhere.25

Wave Intensity Analysis and Wave Separation

Changes in pressure and flow in the circulation result from waves of varying magnitude, character, and direction. The timing, magnitude, character, and direction of such waves can only be definitively established from combined pressure and flow data. Waves can originate either from the proximal (forward-traveling) or distal (backward-traveling) end of the circulation and can be either a compression (“pushing”) or decompression (“sucking”) wave. A compression wave will accelerate or decelerate blood flow depending on its origin: if it arises proximal to the site of measurement, it will increase pressure and accelerate flow, but compression waves of distal origin will increase pressure and decelerate blood flow. Additional information regarding the type and origin of waves in the carotid artery is provided in the online Data Supplement (please see http://hyper.ahajournals.org).

Wave intensity is a measure of the power density of a wave and is given by the product of the simultaneous incremental changes in local pressure (dP) and velocity (dU) in a given time interval.26 Pressure changes attributed to forward-traveling (dPf) and backward-traveling (dB) waves can be separated using equations 1 and 2.

\[
\Delta P_f = 1/2(\Delta P + \rho \times \Delta U)
\]
\[
\Delta P_b = 1/2(\Delta P - \rho \times \Delta U)
\]

where \(\rho\) is the density of blood (1050 kg m\(^{-3}\)) and “c” is the local wave speed. This time-domain approach to wave separation gives results that are essentially identical to impedance-based approaches (data not shown).

Waves were quantified by measuring both the peak of the individual wave intensity and cumulative intensity of each wave (ie, the integral under the wave); this is an index of energy per unit area carried by the wave. Other authors27,28 have used different units to express wave intensity to allow for differences in sampling rates. To convert between units based on a sampling rate of 200 Hz, values in watts per meter squared (W m\(^{-2}\)) should be multiplied by 40 000 to convert to watts per meter squared per second squared (W m\(^{-2}\) s\(^{-2}\)) and by 300 to convert to millimeters of mercury meter per cubic second (mm Hg m s\(^{-3}\)).

Reflection was assessed by 2 measures. First, the wave reflection index was calculated as the sum of the cumulative wave intensity of the reflected compression waves from the head and body (c–1 and c+1, respectively) expressed as a percentage of the cumulative intensity of the initial systolic (S) wave generated by the left ventricle (please see the online Data Supplement for details regarding these waves). The ratio of peak backward:peak forward pressure (Pb/Pf) after wave separation and subtraction of diastolic pressure was also measured as an index of reflection,29 although this ratio may be influenced by decompression waves arising from rereflection of backward compression waves.21 The time of arrival (ΔT) of a specific wave with respect to the S wave was calculated from the intervals between the timing of the peak intensities of the waves generated by the left ventricle, because this is more readily identified than the foot of the wave intensity. The distance (L) to an apparent reflection site in the head was calculated as follows: L = (1/2)c·ΔT,

Manisty et al Wave Reflection in ASCOT 725

Downloaded from hyper.ahajournals.org at Imperial College London (icl) on October 18, 2009
Table 1. Baseline Characteristics of the 2 Treatment Groups

<table>
<thead>
<tr>
<th>Baseline Characteristic</th>
<th>Amlodipine-Based Regimen (N=122)</th>
<th>Atenolol-Based Regimen (N=138)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, n (%)</td>
<td>23 (19)</td>
<td>19 (14)</td>
<td>0.3</td>
</tr>
<tr>
<td>Age, y</td>
<td>64.3 (7.1)</td>
<td>63.3 (7.6)</td>
<td>0.3</td>
</tr>
<tr>
<td>Brachial SBP, mm Hg</td>
<td>162.5 (20.3)</td>
<td>160.7 (18.2)</td>
<td>0.5</td>
</tr>
<tr>
<td>Brachial diastolic BP, mm Hg</td>
<td>94.8 (10.9)</td>
<td>93.5 (10.1)</td>
<td>0.4</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>69.1 (13.7)</td>
<td>68.2 (12.3)</td>
<td>0.6</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>28.1 (3.8)</td>
<td>28.6 (4.4)</td>
<td>0.3</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>82.8 (13.5)</td>
<td>83.1 (15.8)</td>
<td>0.8</td>
</tr>
<tr>
<td>Height, cm</td>
<td>172 (8.6)</td>
<td>170 (9.1)</td>
<td>0.2</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>6.0 (1.1)</td>
<td>5.9 (1.3)</td>
<td>0.8</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/L</td>
<td>1.4 (0.4)</td>
<td>1.3 (0.4)</td>
<td>0.6</td>
</tr>
<tr>
<td>Triglycerides, mmol/L</td>
<td>2.2 (1.4)</td>
<td>2.4 (1.3)</td>
<td>0.1</td>
</tr>
<tr>
<td>Glucose, mmol/L</td>
<td>6.3 (2.7)</td>
<td>6.4 (3.0)</td>
<td>0.7</td>
</tr>
<tr>
<td>Creatinine, mmol/L</td>
<td>99.0 (14.4)</td>
<td>98.7 (19.2)</td>
<td>0.9</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>24 (20)</td>
<td>32 (23)</td>
<td>0.5</td>
</tr>
<tr>
<td>LVH, n (%)</td>
<td>23 (19)</td>
<td>25 (18)</td>
<td>0.9</td>
</tr>
<tr>
<td>Current smoker, n (%)</td>
<td>28 (23)</td>
<td>28 (17)</td>
<td>0.2</td>
</tr>
<tr>
<td>Lipid-lowering therapy, n (%)</td>
<td>40 (33)</td>
<td>37 (27)</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Data are mean (SD) for continuous data or frequency (%) for categorical data. HDL indicates high-density lipoprotein; BMI, body mass index; LVH, left ventricular hypertrophy.

Table 2. Comparison of BP and Other Measures Between Treatment Groups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Amlodipine-Based Regimen (N=121)</th>
<th>Atenolol-Based Regimen (N=138)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brachial SBP, mm Hg</td>
<td>140.4 (12.8)</td>
<td>143.3 (14.8)</td>
<td>0.1</td>
</tr>
<tr>
<td>Brachial diastolic BP, mm Hg</td>
<td>79.5 (7.5)</td>
<td>81.6 (8.9)</td>
<td>0.05</td>
</tr>
<tr>
<td>Brachial pulse pressure, mm Hg</td>
<td>60.7 (12.3)</td>
<td>61.7 (12.8)</td>
<td>0.5</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>71.0 (11.4)</td>
<td>56.0 (9.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No. of antihypertensive agents</td>
<td>1.93 (0.96)</td>
<td>2.42 (0.93)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cardiac output, L/min</td>
<td>4.24 (1.64)</td>
<td>3.81 (1.29)</td>
<td>0.03</td>
</tr>
<tr>
<td>Stroke volume, ml</td>
<td>59.6 (21.6)</td>
<td>64.7 (20.6)</td>
<td>0.07</td>
</tr>
<tr>
<td>Total peripheral resistance, PRU</td>
<td>22.8 (18.1 to 32.7)</td>
<td>25.4 (20.0 to 33.6)</td>
<td>0.05</td>
</tr>
<tr>
<td>cSBP, mm Hg</td>
<td>111.6 (25.5)</td>
<td>117.6 (27.1)</td>
<td>0.08</td>
</tr>
<tr>
<td>Carotid pulse pressure, mm Hg</td>
<td>127.0 (11.9)</td>
<td>132.9 (14.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Peripheral pulse pressure amplification</td>
<td>4.70 (11.0)</td>
<td>51.6 (12.7)</td>
<td>0.003</td>
</tr>
<tr>
<td>Brachial--carotid amplification, mm Hg</td>
<td>1.33 (0.29)</td>
<td>1.22 (0.17)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are mean (SD) or median (interquartile range) for continuous data or frequency (%) for categorical data. Reported timings are with respect to the peak of the ECG R wave. WRI indicates wave reflection index; PRU, peripheral resistance unit.

Results

The 2 treatment groups were well matched (Table 1), and their characteristics were very similar to the main ASCOT cohort and the Conduit Artery Function Evaluation substudy cohort.17 Comparison of the 2 treatment groups showed that heart rate was significantly lower with the atenolol-based regimen. There were no statistically significant differences in brachial BP, although pressures tended to be higher in subjects treated with the atenolol-based regimen (Table 2), in keeping with the findings of the main ASCOT study.17

Statistics

Statistical analysis was performed using StatView (version 5.0, SAS Institute, Inc) and Stata (version 10.0, Stata Corp). Continuous variables are reported as mean (SD) or median (interquartile range) for skewed data. Statistical comparisons between treatment groups were made using an unpaired Student t test or an unpaired nonparametric Wilcoxon rank-sum test for skewed data. The level of statistical significance for between-treatment group comparisons was taken to be P<0.05. Multivariate regression modeling was also performed, and stepwise backward-selection estimation was undertaken using a significance level for removal of P<0.05 on the basis of the Wald test.

cSBP and Wave Reflection

cSBP, carotid pulse pressure, and AIc were significantly lower in the amlodipine group than in the atenolol group (Table 2). Pulse pressure amplification ratio (calculated as peripheral pulse pressure:central pulse pressure), brachial-carotid amplification pressure, and local wave velocity were higher in the amlodipine±perindopril arm than in the atenolol±bendroflumethiazide arm (Table 2). Differences in cSBP between treatment arms remained significant after statistical adjustment for age, sex, heart rate, or all of these variables combined in a multivariate model (Table 3).
Wave intensity analysis indicated that there was no significant difference in the magnitude of the peak or cumulative intensity of the S wave or D wave (Figure 1 and Table 2), but the peak and cumulative intensities of reflected waves from the head (c−1 wave) and the body (c+1 wave), measures of wave reflection (wave reflection index and \( P_b/P_f \)), and \( A_{ic} \) were significantly higher in the atenolol group (Table 2 and Figure 2). Reflected waves from the head were undetectable in 21% and 17% of individuals in the amlodipine and atenolol groups, respectively, and reflected waves from the body were undetectable in 67% and 54% of individuals in the amlodipine and atenolol groups, respectively. The timing of reflected waves and the distance to the apparent reflection sites in the head or in the body did not differ significantly between treatment groups despite the difference in heart rate (Table 2).

**Table 3. Multivariate Regression Models Relating cSBP to Treatment Regimen Adjusted for Other Potential Confounders**

<table>
<thead>
<tr>
<th>Model</th>
<th>( \beta ) (SE)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1</td>
<td>Treatment (unadjusted)</td>
<td>5.49 (1.90)</td>
</tr>
<tr>
<td>Model 2</td>
<td>Treatment</td>
<td>5.81 (1.89)</td>
</tr>
<tr>
<td></td>
<td>Age</td>
<td>0.31 (0.13)</td>
</tr>
<tr>
<td>Model 3</td>
<td>Treatment</td>
<td>5.60 (1.91)</td>
</tr>
<tr>
<td></td>
<td>Sex</td>
<td>2.17 (2.7)</td>
</tr>
<tr>
<td>Model 4</td>
<td>Treatment</td>
<td>6.78 (2.20)</td>
</tr>
<tr>
<td></td>
<td>Heart rate</td>
<td>0.10 (0.09)</td>
</tr>
<tr>
<td>Model 5</td>
<td>Treatment</td>
<td>7.68 (2.22)</td>
</tr>
<tr>
<td></td>
<td>Age</td>
<td>0.35 (0.13)</td>
</tr>
<tr>
<td></td>
<td>Sex</td>
<td>1.71 (3.45)</td>
</tr>
<tr>
<td></td>
<td>Height</td>
<td>4.46 (13.47)</td>
</tr>
<tr>
<td></td>
<td>Heart rate</td>
<td>0.15 (0.09)</td>
</tr>
</tbody>
</table>

**Figure 1.** Example traces comparing measured pressure waveforms \( P_{total} \), \( P_f \), and \( P_b \) separated pressure waveforms and wave intensity between treatment regimens (amlodipine±perindopril vs atenolol±bendroflumethiazide). The shoulder or inflection point in the pressure waveform (Pi) is indicated. The S wave (1), the c−1 wave (2), the c+1 wave (3), and the D wave (4) are shown on the wave-intensity profiles.

**Figure 2.** The wave reflection index was significantly lower in patients randomized to amlodipine-based therapy than atenolol-based therapy (19.8% [10.9%] vs 23.3% [13.3%]; \( P = 0.02 \)).
Wave-intensity analysis and wave separation show that the lower cSBP is attributable to a lower magnitude of wave reflection and not to changes in the timing of reflected waves, differences in heart rate, or changes in the forward wave resulting from ventricular ejection.

These observations extend the findings of another ASCOT substudy (Conduit Artery Function Evaluation), which reported higher central SBP in patients randomized to atenolol and increased central aortic augmentation index estimated from radial tonometry. However, central augmentation index is not simply a measure of wave reflection, and the poor accuracy of radial-derived estimates of central augmentation index make it difficult to draw firm conclusions from this study with regard to wave reflection. Our study observed a significantly higher SBP and AIc in the carotid artery and wave intensity analysis, and separation clearly demonstrated that this was because of increased wave reflection in individual randomized to an atenolol-based regimen. These findings may also offer an explanation for other studies that have used pulse wave analysis to show that β-blockers reduce central SBP less than other antihypertensive medications. Recently, Dart et al also used carotid tonometry to measure central SBP in a substudy of the Second Australian National Blood Pressure Trial but failed to find differences in central BP between patients receiving an angiotensin-converting enzyme inhibitor–based regimen and those receiving a diuretic-based regimen. Our data indicate that the differences between the findings in the Second Australian National Blood Pressure Trial and ASCOT (Conduit Artery Function Evaluation) are unlikely to be related to the method used to measure central pressure (carotid versus radial tonometry) and are more likely to be explained by the different therapeutic regimens used, such as the use of a β-blocker as first-line therapy in 1 treatment arm in ASCOT or some other factor, such as age or cardiovascular risk factor profiles of the participants.

The mechanism by which amlodipine-based therapy alters the magnitude of wave reflection remains to be established, but waves are reflected when they meet sites of impedance mismatching, for example, at bifurcations. Vasodilation is associated with increased wave reflection, and previous studies have also suggested that calcium channel blockers can normalize the impedance pattern of hypertensive subjects as a result of vasodilation. We suggest that the greater vasodilator action of amlodipine-based therapy compared with atenolol-based therapy may account for reduced wave reflection as a result of improved impedance matching. This suggestion is consistent with our observation of a higher total peripheral resistance in people randomized to atenolol-based therapy and the findings of Bleasdale et al, who reported that hypercapnia, a cerebral vasodilator, reduced the magnitude of the reflected c−1 wave in the carotid artery in normal subjects.

It is notable that S-wave intensity was only slightly lower in people receiving atenolol than in those randomized to amlodipine-based therapy and that the difference was not statistically significant. A previous study in dogs reported that intravenous administration of propranolol to dogs resulted in a significant reduction in S-wave intensity. How-
ever, the dose of atenolol used for treatment of hypertension in ASCOT was less (in terms of dose in milligrams per kilogram) than that used experimentally in dogs, and 50 mg of atenolol is insufficient to achieve full \( \beta \)-blockade. In addition, acute and chronic effects of \( \beta \)-blockade on cardiac function may differ. For example, in chronic heart failure, \( \beta \)-blockers increase cardiac index and stroke work index after chronic administration, although they cause a reduction when administered acutely. Additional studies examining the chronic administration, although they cause a reduction when administered acutely. Additional studies examining the acute effect of \( \beta \)-blockers on wave intensity in humans would be of interest.

This study has a number of limitations. The majority of participants were men, and in view of the limited number of women, it should not be assumed that our observations apply equally to both sexes. The lack of pretreatment baseline data means that we cannot comment on how treatment changed wave reflection from the pretreatment state; however, it should be recalled that hardly any individuals were treatment naive, so baseline data would be difficult to interpret. Moreover, with regard to the comparison of treatment regimens, the lack of baseline data is not a major problem, because this was a randomized study, and potential confounders at baseline should be balanced by randomization. Another limitation relates to the treatment regimens themselves: a minority of individuals (26%) were receiving monotherapy (amlodipine or atenolol) at the time of the study, and individuals randomized to atenolol received more add-on therapy than those randomized to amlodipine. The observed differences, therefore, relate only to treatment combinations, and no conclusion should be drawn regarding the effects of the individual agents used as initial monotherapy.

This study also has a number of strengths. It is a large, prospectively randomized clinical trial where carotid BP was measured directly. Unlike previous studies, it measured both BP and flow and was, therefore, able to undertake wave separation and to establish with confidence that the differences in central SBP were attributable to a difference in the magnitude of wave reflection, rather than effects on timing of waves, alterations in heart rate, changes in stroke volume, or modification of the pattern of systolic ejection.

**Perspectives**

The importance of central BP as a target for antihypertensive medication is increasingly accepted. This study has shown that directly measured cSBP is lower with an amlodipine-based regimen than with atenolol-based treatment. This difference is because of a lesser magnitude of wave reflection in patients randomized to an amlodipine-based regimen.

**Acknowledgments**

We are grateful to Sheila Raynor for her expert technical skills and also acknowledge the invaluable support of clinicians, nurses, and support staff involved in ASCOT. We also thank all of the patients who participated in the study.

**Sources of Funding**

We are grateful for an unrestricted educational grant from Pfizer International and the support of the National Institute for Health Research Biomedical Research Centre fund scheme. C.H.M. was supported by a Research Training Fellowship from the Wellcome Trust (077049/Z/05/Z) and the Coronary Flow Trust.

**Disclosures**

None.

**References**


9. Lehman ED. Where is the evidence that radial artery tonometry can be used to accurately and noninvasively predict central arterial blood pressure in patients with diabetes? *Diabetes Care*. 2000;23:869–871.


Downloaded from hyper.ahajournals.org at Imperial College London (ICL) on October 18, 2009


ONLINE SUPPLEMENT

DIFFERENCES IN THE MAGNITUDE OF WAVE REFLECTION ACCOUNT FOR DIFFERENTIAL EFFECTS OF AMLODIPINE- VS ATENOLOL-BASED REGIMEN ON CENTRAL BLOOD PRESSURE: AN ASCOT SUBSTUDY.

Charlotte H Manisty1, Kim H. Parker1, 2, Justin E. Davies1, Darrel P. Francis1, Jamil Mayet1, Simon A McG Thom1, Alun D. Hughes1 on behalf of the ASCOT investigators

1 International Centre for Circulatory Health, NHLI Division, Faculty of Medicine Imperial College London & Imperial College Healthcare NHS Trust, London, United Kingdom.
2 Department of Bioengineering, Faculty of Engineering, Imperial College London

Short Title – Carotid pressure and wave reflection in ASCOT
Appendix 1: The carotid artery wave intensity profile

A wave is a transmitted disturbance that propagates in time and space and the propagation of a wave invariably involves some exchange of energy. In our use, the term wave should be distinguished from the term waveform by which we mean a measured pressure or velocity waveform. Waves in arteries can be classified by their direction of travel (forward or backward) and their relationship to pressure changes (waves occurring during positive changes in pressure are termed compression waves, and waves occurring during negative pressure changes are termed decompression wave).

Wave intensity analysis at the carotid artery reveals a characteristic pattern of waves that are similar to those seen elsewhere in the systemic circulation including the aorta (reviewed in 1). By convention forward travelling waves are assigned positive wave intensity. Details of the type and presumed origins of the waves are described in Figure S1 and accompanying legend.

References


Figure S1.

A) Right common carotid artery and its relation to other arteries, indicating routes followed by waves arising from the head and body and their direction in the common carotid artery.

B) Schematic representation of a typical wave intensity profile in the right common carotid artery. Left ventricular contraction results in a forward travelling compression wave (S wave) that propagates into the carotid artery in early systole causing an acceleration of flow velocity. Subsequently there is a backward-travelling compression wave (c⁻¹) which is due to reflection of the systolic wave from presumed sites of admittance mismatching in territory supplied by the carotid artery (the head). This wave decelerates blood flow velocity in the carotid artery. Subsequently there is a small forward travelling decompression wave (d⁺¹) that causes a deceleration of flow. The d⁺¹ wave is thought to result from re-reflection of c⁻¹ reflected wave at the junction between the carotid and brachiocephalic artery (or the carotid artery and aorta in the left carotid) which generates a decompression or ‘open end’ type of reflection². The magnitude of this re-reflected wave is variable and can be absent in some individuals. The d⁻¹ wave is followed by another forward compression wave (c⁺¹) that is attributed to reflection of the initial systolic S wave from sites of admittance mismatching in the rest of the body³. Although c⁺¹ is a reflected wave (i.e. it travels retrogradely in the aorta (see Figure S1A), it appears as a forward travelling wave in the carotid artery as a result of the anatomical relationship of the carotid artery to the aorta. A forward travelling decompression wave (D wave) appears at the end of systole (protodiastole) and results from a decline the rate of myocardial contraction and this wave contributes to aortic valve closure⁴,⁵.